4928
noevir holdings co.,ltd.
株式会社ノエビアホールディングスNoevir Holdings Co., Ltd. develops, produces, and sells cosmetics, toiletries, medical supplies, and food products in China, Taiwan, South Korea, Hong Kong, Singapore, Thailand, the United States, and Canada. The company's Cosmetics segment develops, produces, and sells skincare products under various brands, including Noevir and Nameraka Honpo; excel make up line products and NOV hypoallergenic cosmetics, as well as provides contract manufacturing services for cosmetics and quasi drugs. Its Pharmaceutical and food business segment produces and sells Nanten Nodo Ame cough drops; functional drinks, such as the Min Min Da Ha; and over-the-counter pharmaceuticals comprising cold remedies, eye drops, and digestive aids, as well as nutritional supplements, and other products. The company's Other segment sells and leases apparel, body fashion, aircraft and ships, air transportation and pilot training business, etc. The company also provides market research. The company sells its products through drug stores and variety stores, and dermatology and medical institutions, as well as Noevir beauty studios and own retail stores. Noevir Holdings Co., Ltd. was founded in 1964 and is headquartered in Kobe, Japan.
Price
¥4,370
Market Cap
¥149.3B
Ent. Value
—
Net Cash
est
—
Shares Out.
34.2M
P / E
18.6×
EV / EBIT
—
P / Book
2.78×
P / NCAV
5.61×
Div. Yield
5.26%
Financials
| Metric |
FY 2025
EDINET ↗ |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|---|
| Net Sales | ¥64.7B | ¥63.8B | ¥62.6B | ¥61.1B | ¥51.3B |
| Cost of Sales | ¥21.4B | ¥20.7B | ¥20.0B | ¥19.1B | ¥18.2B |
| Gross Profit | ¥43.3B | ¥43.2B | ¥42.6B | ¥42.1B | ¥33.0B |
| SG&A | ¥32.2B | ¥31.7B | ¥31.5B | ¥32.0B | ¥24.5B |
| Operating Income | ¥11.1B | ¥11.4B | ¥11.0B | ¥10.1B | ¥8.6B |
| Non-Operating Income | ¥702M | ¥200M | ¥271M | ¥291M | ¥455M |
| Dividend Income | ¥32M | ¥26M | ¥24M | ¥18M | ¥17M |
| Interest Income | ¥94M | ¥50M | ¥30M | ¥10M | ¥8M |
| Non-Operating Expenses | ¥3M | ¥29M | ¥0M | ¥0M | ¥41M |
| Ordinary Income | ¥11.8B | ¥11.6B | ¥11.3B | ¥10.4B | ¥9.0B |
| Pre-tax Income | ¥11.9B | ¥11.6B | ¥11.3B | ¥11.2B | ¥9.0B |
| Income Taxes | ¥3.7B | ¥3.5B | ¥3.5B | ¥3.5B | ¥2.5B |
| Current Tax | ¥3.5B | ¥3.2B | ¥3.2B | ¥2.4B | ¥2.9B |
| Deferred Tax | ¥192M | ¥327M | ¥276M | ¥1.1B | ¥-409M |
| Net Income (owners) | ¥8.0B | ¥8.0B | ¥7.7B | ¥7.6B | ¥6.4B |
| Minority Interest | ¥159M | ¥118M | ¥140M | ¥64M | ¥76M |
| Comprehensive Income | ¥8.1B | ¥8.3B | ¥8.2B | ¥7.9B | ¥7.1B |
| EBITDA | ¥11.9B | ¥12.4B | ¥12.2B | ¥11.6B | ¥10.1B |
| Goodwill Amort. (J-GAAP) | ¥33M | ¥32M | ¥31M | ¥31M | ¥31M |
| EPS | ¥235.10 | ¥233.34 | ¥224.66 | ¥222.20 | ¥186.88 |
| Shares Outstanding | 34.2M | 34.2M | 34.2M | 34.2M | 34.2M |
| Shares Issued (total) | 34.2M | 34.2M | 34.2M | 34.2M | 34.2M |
| Treasury Shares | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |